VolitionRx

US: VNRX

$196.8m market cap

$4.79 last close

VolitionRx is a life sciences company developing novel, simple-to-use, blood-based tests to diagnose a broad range of cancers and other conditions by identifying and measuring nucleosomes in the blood stream. The primary focus is to develop the Nu.Q family of blood-based diagnostics tests for colorectal cancer.

Investment summary

VolitionRx’s proprietary Nu.Q technology detects the level and structure of nucleosomes in the blood using one drop of blood. It is focused on colorectal and lung cancers based on the most recent published proof-of-concept data from studies with clinical-grade Nu.Q assays. Following the proof-of-concept data, Volition and the National Taiwan University will conduct a large-scale lung cancer study. During its Q319 results update, Volition provided more details about the expansion into the veterinary space with its partner Texas A&M University. The development of the so-called Nu.Q Capture technology aims to investigate the use of Nu.Q to purify or enrich tumour-associated nucleosomes.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2017A 0.0 (15.0) (15.1) (57.29) N/A N/A
2018A 0.0 (17.9) (18.0) (48.67) N/A N/A
2019E 0.0 (18.2) (18.4) (45.54) N/A N/A
2020E 0.1 (19.6) (19.7) (46.94) N/A N/A
Industry outlook

The blood-based cancer screening market is in its nascent stages with great potential and serves an unmet medical need. Currently there are few, if any, non-invasive screening methods for the vast majority of cancers.

Last updated on 16/01/2020
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (US$m) 12.5
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 9.4 (11.3) 108.3
Relative* 5.2 (20.0) 64.3
52-week high/low US$6.4/US$2.2
*% relative to local index
Key management
Cameron Reynolds CEO
David Vanston CFO
Jake Micallef Chief Scientific Officer
Scott Powell Director of IR

Content on VolitionRx